President Trump nominated White House domestic policy aide Dr. Heidi Overton on August 18-19, 2026, to serve as FDA commissioner following Marty Makary’s May resignation and acting commissioner Kyle Diamantas’s reported reluctance to accept the permanent role. Confirmation requires Senate approval, beginning with a vote in the Republican-led HELP Committee chaired by Sen. Bill Cassidy, who has already expressed strong reservations over Overton’s involvement in a recent executive order on childhood vaccines, describing it as potentially disqualifying. The narrow Republican Senate majority and committee scrutiny of her policy record on vaccines, mifepristone regulation, and agency priorities create near-term procedural hurdles, while scheduled hearings and any subsequent full-chamber vote will determine whether the nomination advances before the market resolution window closes.
Polymarketデータを参照したAI生成の実験的な要約。これは取引アドバイスではなく、このマーケットの解決方法には一切関係ありません。 · 更新日新規
2026/09/30
9月30日
47%
10月31日
53%
11月30日
50%
12月31日
72%
$1,291 Vol.
9月30日
$586 Vol.
47%
10月31日
$694 Vol.
53%
11月30日
$0 Vol.
50%
12月31日
$11 Vol.
72%
This market will resolve to “Yes” if Heidi Overton is confirmed as Commissioner of the U.S. Food and Drug Administration by September 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to “No”.
If Heidi Overton's nomination is formally withdrawn, or if the Senate rejects the nomination, this market will immediately resolve to “No”.
The Senate must confirm this nominee as Commissioner of the U.S. Food and Drug Administration for this market to resolve to "Yes". Recess appointments without Senate confirmation will not count toward a "Yes" resolution.
The primary resolution source for this market is official information from the U.S. Senate; however, a consensus of credible reporting may also be used.This market will resolve to “Yes” if Heidi Overton is confirmed as Commissioner of the U.S. Food and Drug Administration by October 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to “No”.
If Heidi Overton's nomination is formally withdrawn, or if the Senate rejects the nomination, this market will immediately resolve to “No”.
The Senate must confirm this nominee as Commissioner of the U.S. Food and Drug Administration for this market to resolve to "Yes". Recess appointments without Senate confirmation will not count toward a "Yes" resolution.
The primary resolution source for this market is official information from the U.S. Senate; however, a consensus of credible reporting may also be used.This market will resolve to “Yes” if Heidi Overton is confirmed as Commissioner of the U.S. Food and Drug Administration by November 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to “No”.
If Heidi Overton's nomination is formally withdrawn, or if the Senate rejects the nomination, this market will immediately resolve to “No”.
The Senate must confirm this nominee as Commissioner of the U.S. Food and Drug Administration for this market to resolve to "Yes". Recess appointments without Senate confirmation will not count toward a "Yes" resolution.
The primary resolution source for this market is official information from the U.S. Senate; however, a consensus of credible reporting may also be used.This market will resolve to “Yes” if Heidi Overton is confirmed as Commissioner of the U.S. Food and Drug Administration by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to “No”.
If Heidi Overton's nomination is formally withdrawn, or if the Senate rejects the nomination, this market will immediately resolve to “No”.
The Senate must confirm this nominee as Commissioner of the U.S. Food and Drug Administration for this market to resolve to "Yes". Recess appointments without Senate confirmation will not count toward a "Yes" resolution.
The primary resolution source for this market is official information from the U.S. Senate; however, a consensus of credible reporting may also be used.President Trump nominated White House domestic policy aide Dr. Heidi Overton on August 18-19, 2026, to serve as FDA commissioner following Marty Makary’s May resignation and acting commissioner Kyle Diamantas’s reported reluctance to accept the permanent role. Confirmation requires Senate approval, beginning with a vote in the Republican-led HELP Committee chaired by Sen. Bill Cassidy, who has already expressed strong reservations over Overton’s involvement in a recent executive order on childhood vaccines, describing it as potentially disqualifying. The narrow Republican Senate majority and committee scrutiny of her policy record on vaccines, mifepristone regulation, and agency priorities create near-term procedural hurdles, while scheduled hearings and any subsequent full-chamber vote will determine whether the nomination advances before the market resolution window closes.
This market will resolve to “Yes” if Heidi Overton is confirmed as Commissioner of the U.S. Food and Drug Administration by September 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to “No”.
If Heidi Overton's nomination is formally withdrawn, or if the Senate rejects the nomination, this market will immediately resolve to “No”.
The Senate must confirm this nominee as Commissioner of the U.S. Food and Drug Administration for this market to resolve to "Yes". Recess appointments without Senate confirmation will not count toward a "Yes" resolution.
The primary resolution source for this market is official information from the U.S. Senate; however, a consensus of credible reporting may also be used.
If Heidi Overton's nomination is formally withdrawn, or if the Senate rejects the nomination, this market will immediately resolve to “No”.
The Senate must confirm this nominee as Commissioner of the U.S. Food and Drug Administration for this market to resolve to "Yes". Recess appointments without Senate confirmation will not count toward a "Yes" resolution.
The primary resolution source for this market is official information from the U.S. Senate; however, a consensus of credible reporting may also be used.
マーケット開始日： Aug 20, 2026, 5:43 PM ET
音量
$1,291終了日
2027/01/01マーケット開始日
Aug 20, 2026, 5:43 PM ETResolver
0x65070BE91...This market will resolve to “Yes” if Heidi Overton is confirmed as Commissioner of the U.S. Food and Drug Administration by September 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to “No”.
If Heidi Overton's nomination is formally withdrawn, or if the Senate rejects the nomination, this market will immediately resolve to “No”.
The Senate must confirm this nominee as Commissioner of the U.S. Food and Drug Administration for this market to resolve to "Yes". Recess appointments without Senate confirmation will not count toward a "Yes" resolution.
The primary resolution source for this market is official information from the U.S. Senate; however, a consensus of credible reporting may also be used.This market will resolve to “Yes” if Heidi Overton is confirmed as Commissioner of the U.S. Food and Drug Administration by October 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to “No”.
If Heidi Overton's nomination is formally withdrawn, or if the Senate rejects the nomination, this market will immediately resolve to “No”.
The Senate must confirm this nominee as Commissioner of the U.S. Food and Drug Administration for this market to resolve to "Yes". Recess appointments without Senate confirmation will not count toward a "Yes" resolution.
The primary resolution source for this market is official information from the U.S. Senate; however, a consensus of credible reporting may also be used.This market will resolve to “Yes” if Heidi Overton is confirmed as Commissioner of the U.S. Food and Drug Administration by November 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to “No”.
If Heidi Overton's nomination is formally withdrawn, or if the Senate rejects the nomination, this market will immediately resolve to “No”.
The Senate must confirm this nominee as Commissioner of the U.S. Food and Drug Administration for this market to resolve to "Yes". Recess appointments without Senate confirmation will not count toward a "Yes" resolution.
The primary resolution source for this market is official information from the U.S. Senate; however, a consensus of credible reporting may also be used.This market will resolve to “Yes” if Heidi Overton is confirmed as Commissioner of the U.S. Food and Drug Administration by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to “No”.
If Heidi Overton's nomination is formally withdrawn, or if the Senate rejects the nomination, this market will immediately resolve to “No”.
The Senate must confirm this nominee as Commissioner of the U.S. Food and Drug Administration for this market to resolve to "Yes". Recess appointments without Senate confirmation will not count toward a "Yes" resolution.
The primary resolution source for this market is official information from the U.S. Senate; however, a consensus of credible reporting may also be used.President Trump nominated White House domestic policy aide Dr. Heidi Overton on August 18-19, 2026, to serve as FDA commissioner following Marty Makary’s May resignation and acting commissioner Kyle Diamantas’s reported reluctance to accept the permanent role. Confirmation requires Senate approval, beginning with a vote in the Republican-led HELP Committee chaired by Sen. Bill Cassidy, who has already expressed strong reservations over Overton’s involvement in a recent executive order on childhood vaccines, describing it as potentially disqualifying. The narrow Republican Senate majority and committee scrutiny of her policy record on vaccines, mifepristone regulation, and agency priorities create near-term procedural hurdles, while scheduled hearings and any subsequent full-chamber vote will determine whether the nomination advances before the market resolution window closes.
This market will resolve to “Yes” if Heidi Overton is confirmed as Commissioner of the U.S. Food and Drug Administration by September 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to “No”.
If Heidi Overton's nomination is formally withdrawn, or if the Senate rejects the nomination, this market will immediately resolve to “No”.
The Senate must confirm this nominee as Commissioner of the U.S. Food and Drug Administration for this market to resolve to "Yes". Recess appointments without Senate confirmation will not count toward a "Yes" resolution.
The primary resolution source for this market is official information from the U.S. Senate; however, a consensus of credible reporting may also be used.
If Heidi Overton's nomination is formally withdrawn, or if the Senate rejects the nomination, this market will immediately resolve to “No”.
The Senate must confirm this nominee as Commissioner of the U.S. Food and Drug Administration for this market to resolve to "Yes". Recess appointments without Senate confirmation will not count toward a "Yes" resolution.
The primary resolution source for this market is official information from the U.S. Senate; however, a consensus of credible reporting may also be used.
音量
$1,291終了日
2027/01/01マーケット開始日
Aug 20, 2026, 5:43 PM ETResolver
0x65070BE91...President Trump nominated White House domestic policy aide Dr. Heidi Overton on August 18-19, 2026, to serve as FDA commissioner following Marty Makary’s May resignation and acting commissioner Kyle Diamantas’s reported reluctance to accept the permanent role. Confirmation requires Senate approval, beginning with a vote in the Republican-led HELP Committee chaired by Sen. Bill Cassidy, who has already expressed strong reservations over Overton’s involvement in a recent executive order on childhood vaccines, describing it as potentially disqualifying. The narrow Republican Senate majority and committee scrutiny of her policy record on vaccines, mifepristone regulation, and agency priorities create near-term procedural hurdles, while scheduled hearings and any subsequent full-chamber vote will determine whether the nomination advances before the market resolution window closes.
Polymarketデータを参照したAI生成の実験的な要約。これは取引アドバイスではなく、このマーケットの解決方法には一切関係ありません。 · 更新日
外部リンクに注意してください。
外部リンクに注意してください。
よくある質問